Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Patent
1995-12-28
2000-06-27
Caputa, Anthony C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
4241931, 4241941, 42419511, 4241981, 514 2, A61K 3900, A61K 39385, A61K 3800, A01N 3718
Patent
active
060804092
ABSTRACT:
Disclosed are therapeutic compositions and methods for inducing cytotoxic T cell responses in vitro and in vivo. The therapeutic compositions consist of antigen presenting cells activated by contact with a polypeptide complex constructed by joining together a dendritic cell-binding protein and a polypeptide antigen. Also disclosed are expression vectors and systems for producing the polypeptide complexes.
REFERENCES:
patent: 4861589 (1989-08-01), Ju
patent: 5019384 (1991-05-01), Gefter et al.
patent: 5078996 (1992-01-01), Conlon, III et al.
patent: 5194254 (1993-03-01), Barber et al.
patent: 5334379 (1994-08-01), Pillai et al.
patent: 5616477 (1997-04-01), Price
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5851756 (1998-12-01), Steinman et al.
Berzofsky, J.A., and Berkower, I.J., "Immunogenicity and Antigen Structure," in Fundamental Immunology, Third Edition (Paul, W.E., Ed.) Raven Press, Ltd., New York, NY, pp. 235-274 (1993).
Disis, M.L., et al., "Peptide-Based, but Not Whole Protein, Vaccines Elicity Immunity to HER-2
eu, an Oncogenic Self-Protein," J. Immunol. 156:3151-3158 (1996).
Fisk, B., et al., "Identification of an Immunodominant Peptide of HER-2
eu Protooncogene Recognized by Ovarian Tumor-Specific Cytocotic T Lymphocyte Lines," J. Exp. Med. 181:2109-2117 (1995).
Flamand, V., et al., "Murine Dendritic Cells in Vitro with Tumor Antigen Induce Tumor Resistance in vivo," Eur. J. Immunol. 24:605-610 (1994).
Lin, R.-H., et al., "Induction of Autoreactive B Cells Allows Priming of Autoreactive T Cells," J. Exp. Med. 173:1433-1439 (1991).
Mamula, M.J., et al., "Breaking T Cell Tolerance with Foreign and Self Co-Immunogens," J. Immunol. 149(3) :789-795 (1992).
Schirmbeck, R., et al., "Immunization of Mice with the N-Terminal (1-272) Fragment of Simian Virus 40 Large T Antigen (Without Adjuvants) Specifically Primes Cytotoxic T Lymphocytes," Eur. J. Immunol. 23:1528-1534 (1993).
Schwartz, R.H., "Immunological Tolerance," in Fundamental Immunology, Third Edition (Paul, W.E., Ed.) Raven Press, Ltd., New York, NY, pp. 677-720 (1993).
Tao, M.-H., and Levy, R., "Idiotype/Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein as a Vaccine for B-Cell Lymphoma," Nature 362:755 (1993).
Sharief, R.S., et al., "Human Prostatic Acid Phosphatase: cDNA Cloning, Gene Mapping and Protein Sequence Homology with Lysosomal Acid Phophatase," Biochemical and Biophysical Research Communications, 160(1): 79-86 (1989).
Stauss H.J., et al., "Induction of Cytotoxic T Lymphocytes with Peptides in vitro: Identification of Candidate T-cell Epitopes in Human Papilloma Virus," Proc. Natl. Acad. Sci. USA, 89:7871-7875 (1992).
Takahashi, H., et al., "Induction of CD8.sup.+ Cytotoxic T Cells by Immunization with Purified HIV-1 Envelope Protein in ISCOMs," Nature, 344:873-875 (1990).
Richard et al (Bone Marrow Transplantation vol. 11, Jun. 1993 pp. 473-478.
Grabbe et al (J. Of Leukocyte Biology vol. 55 pp. 695-701), Jun. 1994.
Sunshine et al (J. Of Investigative Dematology vol. 85 pp. 1105-1145), 1985.
Jones et al Eur. J. Clin. Micro. & Infect. Disease 1994 (13) 547-53.
Hodgson et al Eur. J. Biochem. 212 441-446 1993.
Lopez et al Eur. J. Immunology 1993 23: 217-223.
Boog et al J. Immunol. 140 (10) 1988 pp. 3331-3337.
Vihko et al Cancer Research 41 Mar. 1981 pp. 1180-1183.
Dranoff et al Proc. Natl. Acad. Sci. 90:3539 1993.
Laus Reiner
Ruegg Curtis Landon
Wu Hongyu
Caputa Anthony C.
Dendreon Corporation
Judge Linda R.
Navarro Mark
LandOfFree
Immunostimulatory method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunostimulatory method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunostimulatory method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1781997